Advancement in high dose therapy and autologous stem cell rescue in lymphoma

• 作者: Alessandro Isidori Cristina Clissa Federica Loscocco Barbara Guiducci Sara Barulli Lara Malerba Elisa Gabucci Giuseppe Visani
• 来源期刊: 世界干细胞杂志：英文版（电子版）
• 学科: 医学
• 关键词: HODGKIN LYMPHOMA NON-HODGKIN lym- PHOMA High dose
• 年，卷（期）: 2015,（7）
• 页码范围: 1039-1046
• 页数: 8页
• 分类号: R733.1

摘要

A lthough advanced stage aggressive non-Hodgkin’slymphomas and Hodgkin’s disease are thought to be che-motherapy-responsive cancers, a considerable number of patients either relapse or never attain a remission. High-dose therapy(HDT) followed by autologous stem cell transplantation(ASCT) is often the only possibility of cure for most of these patients. However, many controversial issues still remain with respect to HDT/ASCT for lymphomas, including its role for, the optimal timing of transplantation, the best conditioning regimen and the potential use of localized radiotherapy or immunologic methods to decrease post-transplant recurrence. Recently, mainly due to the unavailability of carmustine, several novel conditioning protocols have been clinically developed, with the aim of improving the overall outcome by enhancing the anti-lymphoma effect and, at the same time, by reducing short and long-term toxicity. Furthermore, the better safety profiles of novel approaches would definitively allow patients aged more than 65-70 years to benefit from this therapeutic option. In this review, we will briefly discuss the most relevant and recent data available regarding HDT/ASCT in lymphomas.